Litigation Details for Bayer Pharma AG v. Watson Laboratories, Inc. (D. Del. 2012)

« Back to Dashboard

Bayer Pharma AG v. Watson Laboratories, Inc. (D. Del. 2012)

Docket		Date Filed	2012-04-25
Court	District Court, D. Delaware	Date Terminated	2016-05-02
Cause	35:271 Patent Infringement	Assigned To	Gregory Moneta Sleet
Jury Demand	None	Referred To
Parties	ACTAVIS PHARMA INC.
Patents	8,613,950
Attorneys	Dov P. Grossman
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Bayer Pharma AG v. Watson Laboratories, Inc. (D. Del. 2012)

Date Filed	Document No.	Description	Snippet	Link To Document
2012-04-25				External link to document

Bayer Pharma AG v. Watson Laboratories, Inc. (1:12-cv-00517): Xarelto Patent Litigation Summary

Last updated: September 24, 2026

Bayer Pharma AG v. Watson Laboratories, Inc., C.A. No. 1:12-cv-00517, was a Hatch-Waxman patent case in the U.S. District Court for the District of Delaware involving generic rivaroxaban, the active ingredient in Bayer’s Xarelto anticoagulant. Bayer asserted U.S. Patent No. 7,157,456 against Watson’s abbreviated new drug application (ANDA). The district court upheld the asserted patent against Watson’s validity challenge, and the Federal Circuit affirmed. The case strengthened Bayer’s protection for rivaroxaban’s anticoagulant use during the period covered by the patent.

What drug and patent were at issue in Bayer v. Watson?

The dispute concerned Xarelto, an oral direct factor Xa inhibitor containing rivaroxaban.

Item	Details
Brand drug	Xarelto
Active ingredient	Rivaroxaban
Innovator companies	Bayer Pharma AG and related Bayer entities; Janssen Pharmaceuticals marketed Xarelto in the United States
Generic applicant	Watson Laboratories, Inc., now associated with Actavis and Teva
Court	U.S. District Court for the District of Delaware
Case number	C.A. No. 1:12-cv-00517
Asserted patent	U.S. Patent No. 7,157,456
Patent owner or claimant	Bayer-related entities
Federal Circuit appeal	Bayer Pharma AG v. Watson Laboratories, Inc., 874 F.3d 1316 (Fed. Cir. 2017)
Regulatory pathway	ANDA with a Paragraph IV certification

Patent No. 7,157,456 covers substituted oxazolidinone compounds and related pharmaceutical uses. Rivaroxaban is the principal compound commercially associated with the patent. The litigation focused on claims directed to use of rivaroxaban for preventing thromboembolic disorders, including prevention of venous thromboembolism after orthopedic surgery.

What did Bayer allege against Watson?

Bayer alleged that Watson’s ANDA product would infringe claims of the ’456 patent. A generic applicant filing a Paragraph IV certification represents that a listed patent is invalid, unenforceable, or will not be infringed by the proposed generic product. Bayer filed suit within the statutory 45-day period, triggering the Hatch-Waxman stay of FDA approval.

The case therefore involved two linked issues:

1. Whether Watson’s proposed rivaroxaban product would infringe the asserted claims.
2. Whether the asserted claims were invalid, particularly for obviousness.

Watson challenged the patent’s validity. The principal appellate issue was whether a person of ordinary skill in the art would have had a reasonable expectation of success in selecting rivaroxaban for the claimed anticoagulant use based on the prior art.

What was the court’s decision in the district court?

The District of Delaware ruled for Bayer on the asserted patent claims. The court concluded that the patent was not invalid for obviousness and entered judgment that protected Bayer against the Watson ANDA product.

The court’s analysis recognized that the prior art disclosed factor Xa inhibition and related compound classes, but did not establish that rivaroxaban was an obvious selection for the claimed clinical use. The technical record included uncertainty over the relationship between in vitro activity, in vivo anticoagulant performance, pharmacokinetics, safety, and clinical dosing.

The court rejected the argument that a skilled artisan would have had a sufficient reason and expectation of success to select rivaroxaban from the relevant chemical and pharmacological disclosures. The decision treated the compound’s properties and clinical suitability as material to the obviousness analysis rather than assuming that the existence of related anticoagulants made the claimed use predictable.

How did the Federal Circuit resolve Bayer v. Watson?

The Federal Circuit affirmed the district court in 2017. The appellate court held that the asserted claims were not shown to be obvious.

The Federal Circuit’s reasoning centered on the absence of a persuasive motivation to select rivaroxaban and the lack of a reasonable expectation that it would provide the claimed anticoagulant result. The court also considered the prior art’s disclosure of multiple candidate compounds and the uncertainty surrounding the development of a clinically useful factor Xa inhibitor.

The decision did not establish that pharmaceutical composition or method-of-use patents are categorically non-obvious. Its holding was record-specific. The prior art did not sufficiently direct a skilled artisan to rivaroxaban with the required expectation of success.

The Federal Circuit decision is reported as:

• Bayer Pharma AG v. Watson Laboratories, Inc., 874 F.3d 1316 (Fed. Cir. 2017).

What was the Paragraph IV issue in the Watson ANDA?

Watson’s ANDA included a Paragraph IV certification directed to Bayer’s listed patent rights. Bayer’s infringement action was therefore permitted before FDA approval of the generic product.

Under the Hatch-Waxman framework, the filing of the lawsuit imposed an automatic 30-month stay on final FDA approval, subject to statutory exceptions and court action. The stay gave Bayer time to litigate the patent before Watson could receive final approval for the implicated product.

The case illustrates the commercial effect of a Paragraph IV filing. A generic applicant may challenge a patent before launch, but an unsuccessful validity challenge can delay approval until the patent and regulatory barriers expire or until the innovator reaches a settlement.

What was the Orange Book status of Xarelto?

Xarelto’s U.S. regulatory protection included FDA regulatory exclusivity and listed patent protection.

FDA approval and regulatory exclusivity

The FDA approved Xarelto in 2011 for prevention of deep vein thrombosis after hip or knee replacement surgery. FDA approvals for additional indications followed, including treatment and prevention of recurrence of deep vein thrombosis and pulmonary embolism, and reduction of stroke risk in patients with nonvalvular atrial fibrillation.

Rivaroxaban received new chemical entity exclusivity associated with its initial approval. That exclusivity was distinct from the patent protection asserted in Bayer v. Watson.

Orange Book patent protection

The ’456 patent was listed in connection with Xarelto and was the principal patent in the Watson litigation. Public patent records identify the patent as expiring in 2023 before any applicable patent-term adjustment or pediatric extension. The commercial availability of generic rivaroxaban depended on the full set of listed patents, regulatory exclusivity, and any settlement agreements with generic applicants.

The Orange Book listing did not itself determine the outcome of the validity dispute. It provided the statutory basis for the Paragraph IV certification and the resulting infringement action.

What did Bayer v. Watson decide about patent strength?

The case established that the ’456 patent had meaningful litigation strength against an obviousness attack based on the cited prior art.

Strengths of Bayer’s position

Bayer’s case benefited from several factors:

• The asserted claims were tied to a specific anticoagulant use.
• The prior art disclosed a broad field of factor Xa inhibitors rather than an inevitable selection of rivaroxaban.
• The record included uncertainty concerning clinical performance and safety.
• The district court made factual findings supporting a lack of reasonable expectation of success.
• The Federal Circuit gave deference to the district court’s factual findings and affirmed the legal conclusion of non-obviousness.

Limits of the holding

The ruling did not validate every Xarelto patent or eliminate all generic-entry risk. The decision addressed the asserted claims and the specific record developed against Watson. Other patents, claim constructions, infringement theories, prosecution-history issues, or later-developed prior art could produce different results.

Patent strength also varied by claim type. A compound patent, formulation patent, manufacturing patent, and method-of-use patent create different enforcement and invalidity profiles. Bayer v. Watson principally concerned the ’456 patent and its claimed anticoagulant use.

Did the case involve formulation or manufacturing patents?

The reported Federal Circuit appeal focused on the ’456 patent rather than a separate Xarelto formulation or manufacturing patent.

Xarelto’s broader patent estate has included patent rights involving:

• Rivaroxaban compounds and chemical intermediates.
• Pharmaceutical compositions.
• Dosage regimens.
• Treatment and prevention of thromboembolic conditions.
• Manufacturing processes and intermediates.

The Watson decision should therefore be read as one component of the larger Xarelto patent portfolio. A generic applicant’s launch analysis would require review of all Orange Book-listed patents, non-listed process patents, regulatory exclusivities, and any contractual restrictions created by settlements.

What was the litigation outcome and status?

The case was resolved in Bayer’s favor after the district court judgment and Federal Circuit affirmance.

Procedural event	Outcome
ANDA Paragraph IV filing	Watson challenged Bayer patent protection
Bayer infringement action	Filed in the District of Delaware under C.A. No. 1:12-cv-00517
District court judgment	Bayer prevailed on the asserted patent
Validity challenge	Patent claims upheld against the asserted obviousness challenge
Federal Circuit appeal	Affirmed
Reported appellate decision	874 F.3d 1316
Current significance	Precedent supporting the ’456 patent’s validity against the litigated challenge

There is no basis to treat the case as an ongoing trial proceeding. Its principal legal outcome was the appellate affirmance.

Did Bayer and Watson enter a settlement agreement?

The reported appellate decision resolved the litigated validity issue. A separate, publicly documented settlement term for this specific docket should not be inferred from the existence of later generic-entry agreements involving Xarelto or other defendants.

Pharmaceutical patent settlements can establish launch dates that differ from the nominal patent expiration date. They may also include licenses, covenants not to sue, authorized-generic arrangements, or restrictions tied to particular strengths and indications. Those terms must be attributed to the specific settlement and defendant. The Bayer v. Watson appellate record establishes the judgment and affirmance, not a universal launch date for all generic rivaroxaban products.

Which companies challenged Xarelto patents?

Xarelto faced broad generic competition as the principal patent and regulatory barriers approached expiration. Multiple generic manufacturers pursued ANDA strategies involving rivaroxaban, and Bayer and Janssen entered separate litigation or settlement discussions with applicants in the field.

The Watson case is commercially important because it was one of the early high-value challenges to Xarelto’s U.S. patent protection. It did not, by itself, determine the timing of every competitor’s launch. Each applicant’s risk depended on:

• The patents identified in its ANDA certification.
• The dosage forms and strengths covered by its application.
• The indication or labeling carve-outs.
• The outcome of its own litigation.
• Any settlement or license terms.

How did the decision affect generic launch risk?

The decision increased the risk of an early Watson launch before the ’456 patent’s enforceable protection ended. A launch during the patent term could have exposed Watson to infringement liability, damages, an injunction, or other relief.

For Bayer, the ruling supported continued branded sales during the remaining patent term. For Watson, it removed one route to an early commercial launch unless the company prevailed on another patent, obtained a license, reached a settlement, or pursued a non-infringing product strategy.

The decision did not prevent eventual generic entry after the relevant patent and regulatory barriers expired. It primarily delayed or complicated entry based on the specific patent claims asserted against Watson.

How does Bayer v. Watson compare with other Xarelto patent risks?

Risk category	Bayer v. Watson position	Broader Xarelto assessment
Compound protection	Not the central appellate issue	Depends on the specific compound claims and expiration data
Method-of-use protection	Central to the ’456 patent analysis	Can vary by indication and label strategy
Formulation patents	Not the principal issue in the appeal	May create separate infringement and validity questions
Manufacturing patents	Not resolved by the decision	Can affect supply-chain freedom to operate
Regulatory exclusivity	Separate from the judgment	Controlled by FDA approval dates and exclusivity rules
Paragraph IV risk	Watson’s challenge failed on appeal	Other ANDA applicants may have different records
Settlement risk	Not established by the appellate opinion	Must be analyzed by defendant and agreement
Biosimilar risk	Not applicable	Xarelto is a small-molecule drug, so generic rather than biosimilar competition applies

Xarelto is a small-molecule medicine. The relevant competitive threat is generic rivaroxaban, not biosimilar substitution under the Public Health Service Act.

What is the business significance of the case?

Bayer v. Watson demonstrated the value of a focused method-of-use patent when the prior art disclosed a broad pharmacological field but did not make the claimed clinical selection predictable.

The ruling supported Bayer’s ability to maintain market protection for rivaroxaban during the ’456 patent term. Its value was highest before generic entry and during the period when Xarelto generated substantial anticoagulant revenue. The commercial effect declined as the patent approached expiration and competing generic applicants obtained approval or settlement rights.

The case also illustrates the limits of relying on one patent. A durable pharmaceutical franchise requires coordinated protection across chemical structure, formulation, dosing, indications, manufacturing, regulatory exclusivity, and litigation strategy.

Key Takeaways

• Bayer Pharma AG sued Watson in the District of Delaware over a Paragraph IV ANDA for generic rivaroxaban.
• The litigation centered on U.S. Patent No. 7,157,456, associated with Xarelto.
• The district court upheld the patent against Watson’s obviousness challenge.
• The Federal Circuit affirmed in Bayer Pharma AG v. Watson Laboratories, Inc., 874 F.3d 1316 (Fed. Cir. 2017).
• The decision found that the prior art did not provide a sufficient motivation and reasonable expectation of success to select rivaroxaban for the claimed use.
• The case involved a small-molecule generic challenge, not a biosimilar dispute.
• The appellate ruling strengthened Bayer’s position against early Watson entry but did not resolve every Xarelto patent or every generic applicant’s rights.
• Any launch date based on settlement must be tied to the specific defendant and agreement.

FAQs About Bayer Pharma AG v. Watson Laboratories

What was the case number for Bayer v. Watson?

The case was C.A. No. 1:12-cv-00517 in the U.S. District Court for the District of Delaware.

Which Xarelto patent did Watson challenge?

Watson challenged U.S. Patent No. 7,157,456, which covered rivaroxaban-related technology and anticoagulant use claims asserted against the ANDA product.

Did Watson win the Xarelto patent appeal?

No. The Federal Circuit affirmed the district court’s ruling for Bayer and upheld the patent against the asserted obviousness challenge.

Was Xarelto’s patent protection a biologic exclusivity issue?

No. Xarelto is a small-molecule drug. Generic competition proceeds through the ANDA pathway rather than the biosimilar pathway.

Does the Bayer v. Watson decision establish the generic launch date for all rivaroxaban products?

No. The decision applies to the litigated patent and Watson’s ANDA dispute. Other applicants’ launch dates depend on their patents, FDA status, litigation outcomes, and settlement terms.

References

1. Bayer Pharma AG v. Watson Laboratories, Inc., 874 F.3d 1316 (Fed. Cir. 2017).

2. U.S. Food and Drug Administration. (n.d.). Orange Book: Approved drug products with therapeutic equivalence evaluations. https://www.accessdata.fda.gov/scripts/cder/ob/

3. U.S. Food and Drug Administration. (2011). FDA approves Xarelto to reduce the risk of blood clots in patients undergoing knee or hip replacement surgery. https://www.fda.gov/

4. U.S. Patent No. 7,157,456. (2007). Oxazolidinones and their use. U.S. Patent and Trademark Office.